These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7683228)

  • 21. Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.
    Steinke B; Bross K; Reinold HM; Heim ME; Schalk KP; Heidemann E; Josten K; Arnold H; Manegold C; Hoffman I
    Eur J Cancer; 1992; 28(1):100-4. PubMed ID: 1373634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
    Steinke B; Kraft A; Reinold HM; Heim ME; Löffler B; Heidemann E; Richter C; Josten K; Bross K; Hofmann I
    Onkologie; 1989 Feb; 12(1):19-21. PubMed ID: 2469999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
    Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
    J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-hodgkins lymphoma.
    Mead G; Woodcock J; Young C
    Clin Evid; 2003 Jun; (9):1-21. PubMed ID: 12967352
    [No Abstract]   [Full Text] [Related]  

  • 25. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
    Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
    Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CHOP versus intensive regimens in non-Hodgkin's lymphoma.
    Longo DL; DeVita VT; Young RC
    N Engl J Med; 1993 Aug; 329(8):580-1; author reply 581-2. PubMed ID: 7687747
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
    Magrath I; Adde M; Shad A; Venzon D; Seibel N; Gootenberg J; Neely J; Arndt C; Nieder M; Jaffe E; Wittes RA; Horak ID
    J Clin Oncol; 1996 Mar; 14(3):925-34. PubMed ID: 8622041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disseminated nonlymphoblastic lymphoma of childhood: a Childrens Cancer Group study, CCG-552.
    Finlay JL; Anderson JR; Cecalupo AJ; Hutchinson RJ; Kadin ME; Kjeldsberg CR; Provisor AJ; Woods WG; Meadows AT
    Med Pediatr Oncol; 1994; 23(6):453-63. PubMed ID: 7935170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
    Gerhartz HH; Wilmanns W; Brittinger G; Engelhard M; Heinz R; Huhn D; Meusers P; Siegert W; Stacher A; Thiel E
    Onkologie; 1989 Feb; 12(1):22-6. PubMed ID: 2470000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.
    Diviné M; Lepage E; Brière J; Pautier P; Dupriez B; Lederlin P; Mineur P; Tilly H; Blanc M; Audhuy B; Herbrecht R; Coiffier B; Reyes F
    J Clin Oncol; 1996 Jan; 14(1):240-8. PubMed ID: 8558204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study.
    Bowman WP; Shuster JJ; Cook B; Griffin T; Behm F; Pullen J; Link M; Head D; Carroll A; Berard C; Murphy S
    J Clin Oncol; 1996 Apr; 14(4):1252-61. PubMed ID: 8648381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
    Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G
    Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience with ifosfamide combinations in malignant lymphomas.
    Cabanillas F
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):78-81. PubMed ID: 2649986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
    Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
    J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
    Inoue R; Natazuka T; Shimoyama M; Tamekane A; Kajimoto Y; Iwata N; Matsuoka H; Chihara K; Matsui T
    Leuk Lymphoma; 2000 Jan; 36(3-4):315-21. PubMed ID: 10674903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group.
    Siegert W; Agthe A; Griesser H; Schwerdtfeger R; Brittinger G; Engelhard M; Kuse R; Tiemann M; Lennert K; Huhn D
    Ann Intern Med; 1992 Sep; 117(5):364-70. PubMed ID: 1380221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.